Page last updated: 2024-12-07

bay n 7133

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vibunazole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123676
CHEMBL ID4757643
SCHEMBL ID269849
MeSH IDM0113441

Synonyms (49)

Synonym
bay-n-7133
vibunazole
bay n-7133
D02585
80456-55-9
bay n 7133
alpha-tert-butyl-alpha-((4-chlorophenoxy)methyl)-1h-1,2,4-triazol-1-ethanol
einecs 279-475-3
1-(4-chlorophenoxy)-3,3-dimethyl-2-(1,2,4-triazol-1-ylmethyl)butan-2-ol
1-(4-chlorophenoxy)-3,3'-dimethyl-2-(1,2,4-triazol-1-yl)methyl-2-butanol
bay n7133
unii-lf5yfq552k
lf5yfq552k ,
SCHEMBL269849
2-(4-chlorophenoxymethyl)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)-2-butanol
2-(4-chlorophenoxy-methyl)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)-butan-2-ol
OCQPZTCGZAFWSG-UHFFFAOYSA-N
2-(4-chlorophenoxy-methyl)-3,3-dimethyl-1-(1,2,4-triazole-1-yl)butan-2-ol
2-(4-chlorophenoxy-methyl)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-ol
2-(4-chlorophenoxy-methyl)-3,3-dimethyl-1-(1,2,4-triazol-1yl)butan-2-ol
alpha-tert-butyl-alpha-[(4-chlorophenoxy)methyl]-1h-1,2,4-triazol-1-ethanol
AKOS030531203
HY-100121
CS-0018100
2-((1h-1,2,4-triazol-1-yl)methyl)-1-(4-chlorophenoxy)-3,3-dimethylbutan-2-ol
1h-1,2,4-triazole-1-ethanol, alpha-((4-chlorophenoxy)methyl)-alpha-(1,1-dimethylethyl)-, (+)-
(-)-alpha-((4-chlorophenoxy)methyl)-alpha-(1,1-dimethylethyl)-1h-1,2,4-triazole-1-ethanol
unii-s72s9rve68
1h-1,2,4-triazole-1-ethanol, alpha-((4-chlorophenoxy)methyl)-alpha-(1,1-dimethylethyl)-, (-)-
(+)-alpha-((4-chlorophenoxy)methyl)-alpha-(1,1-dimethylethyl)-1h-1,2,4-triazole-1-ethanol
unii-nr0g3w568c
bay-r-2302
1h-1,2,4-triazole-1-ethanol, .alpha.-((4-chlorophenoxy)methyl)-.alpha.-(1,1-dimethylethyl)-, (-)-
NR0G3W568C ,
S72S9RVE68 ,
(+/-)-1-(4-chlorophenoxy)-3,3-dimethyl-2-(1,2,4-triazol-1-ylmethyl)butan-2-ol
bay-n-7133, (-)-
vibunazole, (-)-
104358-26-1
1h-1,2,4-triazole-1-ethanol, .alpha.-((4-chlorophenoxy)methyl)-.alpha.-(1,1-dimethylethyl)-, (+)-
(+)-.alpha.-((4-chlorophenoxy)methyl)-.alpha.-(1,1-dimethylethyl)-1h-1,2,4-triazole-1-ethanol
bay-r-2303
(-)-.alpha.-((4-chlorophenoxy)methyl)-.alpha.-(1,1-dimethylethyl)-1h-1,2,4-triazole-1-ethanol
vibunazole, (+)-
104358-25-0
1h-1,2,4-triazole-1-ethanol, .alpha.-((4-chlorophenoxy)methyl)-.alpha.-(1,1-dimethylethyl)-
1-(4-chlorophenoxy)-3,3-dimethyl-2-[(1h-1,2,4-triazol-1-yl)methyl]butan-2-ol
DTXSID201001251
CHEMBL4757643

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies indicated lower peak vibunazole and 9139 serum concentrations, and reduced area-under-curve (AUC), after 26 days of treatment, as against single dose administration."( New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice.
Lefler, E; Stevens, DA, 1985
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" Flucytosine combined with amphotericin B produced little or no reduction of the MICs at which 90% of the strains were inhibited compared with amphotericin B alone."( In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.
Gerding, DN; Harris, C; Hughes, CE; Moody, JA; Peterson, LR, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
" One day after challenge, oral treatment with BAY n7133, ketoconazole, or a placebo control was begun BAY n7133 was well absorbed after oral administration and penetrated all tissues evaluated."( Treatment of experimental murine aspergillosis with BAY n7133.
Drutz, DJ; Graybill, JR; Kaster, SR, 1983
)
0.27
" The absolute bioavailability of oral vibunazole in the dog was estimated to be about 70%."( Pharmacokinetics of the oral triazole antimycotic vibunazole in animals.
Plempel, M; Ritter, W, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (97.30)18.7374
1990's1 (2.70)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.59 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.70%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]